A Multi-Center Phase 2 Study of Combined Modality Treatment With Ruxolitinib, Decitabine, and Donor Lymphocyte Infusion for Post-Transplant Relapse of AML or MDS
Latest Information Update: 09 Nov 2023
At a glance
- Drugs Decitabine (Primary) ; Ruxolitinib (Primary) ; Lymphocyte replacements
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
Most Recent Events
- 01 May 2023 Results assessing efficacy of of 10-Day Decitabine, Dose-Escalated Donor Lymphocyte Infusion, and Ruxolitinib for Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Cell Transplantation published in the Transplantation and Cellular Therapy
- 02 Nov 2022 Status changed from active, no longer recruiting to completed.
- 16 Feb 2022 Planned primary completion date changed from 1 Jan 2025 to 1 Jul 2022.